Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
HOME > COMMENTARY
COMMENTARY
- Japan Should Promote Personalized Cancer Treatment
July 26, 2010
- METI Reports on “Patent Box”Taxation System in Its Vision 2010
July 5, 2010
- How Will Generics-Only Companies Will Compete with Major New Entrants?
June 28, 2010
- Mr Hasegawa Calls For Cooperation with Asian Countries
June 21, 2010
- PMDA Consultation for Clinical Drug Development in Japan
April 26, 2010
- Taiyo Needs to Restart from Scratch
April 19, 2010
- Drug Companies Have No Time to Lose under New Pricing System
March 29, 2010
- Wholesalers, Pharmacy Chains to Ally to Improve Their Business
March 22, 2010
- New Pricing System Gives Makers Good Chance to Break from Old Business Practices
March 8, 2010
- Transfer Limited Financial Resources to Parties Who Make Effort to Provide Better Services
March 1, 2010
- Korosho Moves to Change Its Vaccine Policy
February 22, 2010
- Prospects of the Japanese Pharmaceutical Industry in 2010
February 15, 2010
- Number of Entrants into Market for Biosimilars Increases, But Barriers Are Still High
February 8, 2010
- New Pricing System to Make e-Detailing More Important
February 1, 2010
- Verify Acceptability of Prices before Revising Pricing Rule
November 30, 2009
- Number of Holders of Designated Disease Treatment Beneficiary Certificate Up to 647,604
November 30, 2009
- Pharmacology of Aging and Longevity: Looking for Anti-Aging Therapeutics (2)
November 2, 2009
- Pharmacology of Aging and Longevity: Looking for Anti-Aging Therapeutics (1)
November 2, 2009
- How Not to License a Drug into Japan
October 12, 2009
- TOPICS/Abbott Named One of the "Best Places to Launch a Career" by BusinessWeek
October 5, 2009
ページ
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…